Trial intelligence / Profile preview

Jaktinib cream in mild to moderate atopic dermatitis

CTR20201162Phase 2Completed

Sponsor
Suzhou Zelgen Biopharmaceuticals
Start
Jun 2020
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of jaktinib in atopic dermatitis (AD), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Jun 2020; status: completed.

02

Drugs

jaktinib
03

Conditions

atopic dermatitis (AD)

Beyond the preview

Go deeper on CTR20201162.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20201162.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call